汇宇制药：西咪替丁注射液获药品注册证书

Group 1 - The core point of the article is that Huiyu Pharmaceutical (688553) has received approval from the National Medical Products Administration for its product, Cimetidine Injection, which is primarily indicated for the treatment of gastrointestinal ulcers [1] Group 2 - The approval of Cimetidine Injection is a significant milestone for the company, as it expands its product portfolio in the pharmaceutical market [1] - The indication for gastrointestinal ulcers highlights the company's focus on addressing critical health issues within the digestive system [1] - This development may enhance the company's competitive position in the pharmaceutical industry, particularly in the area of gastrointestinal treatments [1]